Not available in the U.S.
Luseogliflozin
LUSEFI
What it isSelective sodium-glucose cotransporter-2 (SGLT2) inhibitor; lowers blood glucose by blocking proximal-tubule renal glucose reabsorption and increasing urinary glucose excretion.
Why this oneApproved in Japan (not the US) for type 2 diabetes, providing insulin-independent glycemic control with modest weight loss and little intrinsic hypoglycemia risk.
What limits itCarries the SGLT2-class cautions—genital mycotic and urinary tract infections, volume depletion/hypotension, and rare euglycemic diabetic ketoacidosis.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning.
Classes and tags
Clinical profile
Open Luseogliflozin in the interactive console ↗
Self-check
- Is luseogliflozin approved in the US?
No; approved in Japan. - What uncommon ketoacidosis risk does luseogliflozin share with SGLT2 inhibitors?
Euglycemic diabetic ketoacidosis.